

Pituitary Disorders

[View the current Pituitary Disorders InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Pituitary_Disorders.html) (PDF)

(http://www.bioportfolio.com/indepth/Pituitary_Disorders.html) - Regularly Updated.



Recent Publications on Pituitary Disorders:

- [\[Treatment of pituitary adenomas\]](#)
*According to epidemiological studies, the prevalence of pituitary adenomas...*18th November, 2009
Pecsi Tudományegyetem, Klinikai Központ I. Belgyógyászati Klinika Pecs.- Orv Hetil. 2009 Sep 27;150(39):1803-10. ([DOI Direct Link](#))
- [Assessment of normal perisellar anatomy in 1.5 T T2-weighted MRI and comparison with the anatomic criteria defining cavernous sinus invasion of pituitary adenomas.](#)
*OBJECTIVE: The study aimed to evaluate the anatomical relations of sellar...*17th November, 2009
Department of Neurosurgery, Johannes Wesling Klinikum, Hans-Nolte-Strasse- Cen Eur Neurosurg. 2009 Aug;70(3):130-6. Epub 2009 Aug 21. ([DOI Direct Link](#))
- [An approach to the management of patients with residual Cushing's disease.](#)
*The evaluation and management of patients with residual Cushing's disease...*10th November, 2009
California Center for Pituitary Disorders, University of California at San- J Neurooncol. 2009 Sep;94(3):313-9. Epub 2009 Apr 19. ([DOI Direct Link](#))
- [Incidence and pathophysiology of severe hyponatraemia in neurosurgical patients.](#)
*BACKGROUND: Hyponatraemia is a well-recognised complication of...*3rd November, 2009
Department of Academic Endocrinology, Beaumont Hospital, Dublin, Ireland.- Postgrad Med J. 2009 Apr;85(1002):171-5. ([DOI Direct Link](#))
- [Recent advances in the treatment of acromegaly.](#)
*PURPOSE OF REVIEW: Description of recent outcomes and approaches to the...*23rd October, 2009
California Center for Pituitary Disorders at UCSF, Department of- Curr Opin Endocrinol Diabetes Obes. 2009 Aug;16(4):304-7. ([DOI Direct Link](#))
- [Hypothalamic-pituitary axis deficiency following traumatic brain injury in a dog.](#)
*OBJECTIVE: To describe endocrine dysfunction associated with traumatic...*21st August, 2009
Angell Animal Medical- J Vet Emerg Crit Care (San Antonio). 2009 Jun;19(3):269-74. ([DOI Direct Link](#))
- [Management of recurrent and refractory Cushing's disease with reoperation and/or proton beam radiosurgery.](#)
*The pituitary gland secretes vital trophic hormones that maintain...*1st May, 2009
The California Center for Pituitary Disorders, The University of- Clin Neurosurg. 2008;55:141-4.
- [The low-dose \(1 mug\) Cosyntropin Test \(LDT\) for Primary Adrenocortical Insufficiency: Defining the Normal Cortisol Response and Report on First Patients with Addison Disease Confirmed with LDT.](#)
*BACKGROUND: The validity of low-dose 1 mug cosyntropin test (LDT) is...*10th April, 2009
1Department of Endocrinology, National Institute of Endocrinology and- Exp Clin Endocrinol Diabetes. 2009 Apr 8. ([DOI Direct Link](#))

- [A simple and cost-effective approach to assessment of pituitary adrenocorticotropin and growth hormone reserve: combined use of the overnight metyrapone test and insulin-like growth factor-I standard deviation scores.](#)
CONTEXT: The insulin tolerance test (ITT) is the gold standard for... 17th December, 2008
 Department of Endocrinology and Diabetes, Adelaide and Meath Hospital,- J Clin Endocrinol Metab. 2008 Oct;93(10):3763-8. Epub 2008 Jul 29. ([DOI Direct Link](#))
- [Management of recurrent and refractory Cushing disease.](#)
Cushing disease is most frequently caused by pituitary adenomas that... 13th November, 2008
 Neurological Surgery, The California Center for Pituitary Disorders,- Nat Clin Pract Endocrinol Metab. 2008 Oct;4(10):560-8. Epub 2008 Aug 19. ([DOI Direct Link](#))
- [Practical pituitary pathology: what does the pathologist need to know?](#)
CONTEXT: The sellar region is the site of frequent pathology. The... 30th August, 2008
 Department of Pathology, University Health Network, Toronto, Ontario,- Arch Pathol Lab Med. 2008 Aug;132(8):1231-40.
- [Pituitary disorders: an overview for the general physician.](#)
The pituitary gland is responsible for the production of the trophic... 12th August, 2008
 North Thames Central Rotation, Department of Endocrinology, University- Br J Hosp Med (Lond). 2008 Apr;69(4):198-204.
- [Update in pituitary disease.](#)
The pituitary gland secretes vital trophic hormones that maintain... 11th April, 2008
 Cedars-Sinai Medical Center-David Geffen UCLA School of Medicine, Los- J Clin Endocrinol Metab. 2008 Feb;93(2):331-8. ([DOI Direct Link](#))
- [Hypopituitarism after multiple concussions: a retrospective case study in an adolescent male.](#)
OBJECTIVE: To describe the development of hypopituitarism in an adolescent... 6th February, 2008
 Department of Exercise & Sport Sciences, Ithaca College, Ithaca, NY 14850,- J Athl Train. 2007 Jul-Sep;42(3):431-9.
- [An evaluation of the thyrotrophin-releasing hormone stimulation test in paediatric clinical practice.](#)
AIM: The aim of this retrospective study was to evaluate the clinical... 11th January, 2008
 Department of Paediatric Biochemistry, Royal Hospital for Sick Children,- Horm Res. 2008;69(1):53-9. Epub 2007 Dec 4. ([DOI Direct Link](#))

Pituitary Disorders Patents:



- 6368592- [Method of delivering oxygen to cells by electrolyzing water](#)
- 6723841- [Corticotropin-releasing factor2 receptors](#)
- 6759222- [14815, a human kinase family member and uses therefor](#)
- 6787345- [55053, a novel human eukaryotic kinase and uses therefor](#)
- 6827931- [Method for treating endocrine disorders](#)
- 6862466- [Methods of monitoring glucose levels in a subject and uses thereof](#)
- 6897056- [32544, a novel human phospholipase C and uses thereof](#)
- 6900044- [68999, a human ubiquitin carboxyl-terminal hydrolase family member and uses therefor](#)
- 6911335- [57316 and 33338, human ubiquitin carboxyl terminal hydrolases and uses therefor](#)
- 6960651- [TANGO 332 polypeptides](#)
- 6967237- [Ghrelin analogs](#)

- 6706868- [Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease](#)
- 6673823- [Use of peroxisome proliferator activated receptor \(PPAR\)-gamma. ligands as a treatment for pituitary tumors and associated conditions, such as Cushing's syndrome](#)
- 6627423- [21481, a novel dehydrogenase molecule and uses therefor](#)
- 6395742- [2,4-diaminopyrimidine derivatives](#)
- 6479491- [Disubstituted morpholine, oxazepine or thiazepine derivatives, their preparation and their use as dopamine d4 receptor antagonists](#)
- 6485955- [Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease](#)
- 6500657- [33167, a novel human hydrolase and uses therefor](#)
- 6504081- [Methods and uses for transposon-based gene targeting](#)
- 6511834- [32142,21481,25964,21686, novel human dehydrogenase molecules and uses therefor](#)
- 6518411- [RGS compositions and therapeutic and diagnostic uses therefor](#)
- 6548736- [7B2 knockout transgenic animals as models of endocrine disease](#)
- 6573363- [Cystine knot protein and materials and methods for making it](#)
- 6613555- [32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor](#)
- 6972187- [OAT5 molecules and uses therefor](#)
- 6979564- [80090, human fucosyltransferase nucleic acid molecules and uses thereof](#)
- 7348156- [7B2 knockout transgenic animals as models of endocrine disease](#)
- 7351566- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552, and 65577 molecules and uses therefor](#)
- 7385036- [Human tango 509 polypeptides](#)
- 7411054- [25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor](#)
- 7420044- [Nucleic acid and protein homologs and uses thereof](#)
- 7456253- [Growth hormone releasing peptides](#)
- 7459530- [Tango 405 polypeptides and uses thereof](#)
- 7494793- [21686, dehydrogenase](#)
- 7547766- [Anti-tango294 antibodies and uses thereof](#)
- 7589058- [Ghrelin analogs](#)
- 7264926- [Nucleoside Phosphatase](#)
- 7228163- [Methods of monitoring glucose levels in a subject and uses thereof](#)
- 7166428- [62112, a novel human dehydrogenase and uses thereof](#)
- 7001753- [59079 and 12599, protein kinase family members and uses therefor](#)
- 7034118- [Corticotropin-releasing factor.sub.2 receptors](#)
- 7037889- [Pharmaceutical compositions for sustained drug delivery](#)
- 7041474- [Nucleic acid encoding human tango 509](#)
- 7045325- [32142, 21481, 25964, 21686, novel dehydrogenase molecules and uses therefor](#)
- 7049091- [14815, a human kinase family member and uses therefor](#)
- 7087430- [Human VNO cDNA libraries](#)
- 7094587- [16002 Molecules and uses therefor](#)
- 7141543- [RIEG compositions and therapeutic and diagnostic uses therefor](#)
- 7160694- [Nucleic acids encoding TANGO405 and functional fragments and uses thereof](#)
- 7611879- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

